Research programme: elongation factor 2 kinase inhibitors - Longevica PharmaceuticalsAlternative Names: Research programme: EF2 kinase inhibitors - Longevica Pharmaceuticals
Latest Information Update: 16 Jul 2016
At a glance
- Originator Longevica Pharmaceuticals
- Mechanism of Action Elongation factor 2 kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chemoprotection
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chemoprotection in USA
- 24 Nov 2008 Preclinical trials in Chemoprotection in USA (unspecified route)